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Abstract
Obesity and type 2 diabetes increase worldwide at an epidemic rate. It is expected that by the year 2030 around 500 million
people will have diabetes; predominantly type 2 diabetes. The CCN family of proteins has become of interest in both metabolic
and other common human diseases because of their effects on mesenchymal stem cell (MSCs) proliferation and differentiation as
well as being important regulators of fibrosis. We here review current knowledge of the WNT1 inducible signaling pathway
protein 2 (CCN5/WISP2). It has been shown to be an important regulator of both these processes through effects on both the
canonical WNT and the TGFβ pathways. It is also under normal regulation by the adipogenic commitment factor BMP4, in
contrast to conventional canonicalWNT ligands, and allowsMSCs to undergo normal adipose cell differentiation. CCN5/WISP2
is highly expressed in, and secreted by, MSCs and is an important regulator of MSCs growth. In a transgenic mouse model
overexpressing CCN5/WISP2 in the adipose tissue, we have shown that it is secreted and circulating in the blood, the mice
develop hypercellular white and brown adipose tissue, have increased lean body mass and enlarged hypercellular hearts. Obese
transgenic mice had improved insulin sensitivity. Interestingly, the anti-fibrotic effect of CCN5/WISP2 is protective against heart
failure by inhibition of the TGFβ pathway. Understanding how CCN5/WISP2 is regulated and signals is important and may be
useful for developing new treatment strategies in obesity and metabolic diseases and it can also be a target in regenerative
medicine.
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Abbreviations
FDR First Degree Relatives
MS Metabolic Syndrome
MSCs Mesenchymal stem cells
WISP2 WNT1 inducible signaling pathway protein 2
Multipotential mesenchymal stem cells
and their regulation by CCN5/WISP2
Mesenchymal stem cells (MSCs) are self-renewing,
multipotent cells with stem cell-like characteristics found in
adult tissues. These cells have the capacity to differentiate into
multiple cell types with a broad variety of physiological func-
tions and are present in nearly all tissues where they are in-
volved in regeneration and cellular homeostasis.
MSCs from the bone marrow are the most frequently in-
vestigated. However, MSCs from other tissues such as the
peripheral blood, adipose tissue, cardiac tissue, and perinatal
tissues also have potential to proliferate and differentiate into
the adipogenic, chondrogenic, and osteogenic lineages and,
subsequently, to differentiate into functional cardiomyocytes,
endothelial, neural and insulin-producing cells (Hass et al.
2011).
The CCN family of proteins play an important role inMSC
regulation and its expression is high in both embryonic and
adult tissue. CCNs play an important role during embryonic
development, wound healing, injury repair, angiogenesis, and
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fibrosis and can interact with, and modulate, signals by
integrins, BMPs, VEGF, Notch, and canonical WNTs. (Jun
and Lau 2011; Klenotic et al. 2016; Zuo et al. 2010).
Canonical WNT signaling is of particular importance for the
determination of MSC fate and promotes entry of mesenchy-
mal precursor cells into the myocyte and osteocyte lineages
while suppressing commitment to the adipocytic lineage and
adipose cell terminal differentiation (Armani et al. 2010;
Christodoulides et al. 2009; Gustafson et al. 2009; Gustafson
and Smith 2010). One of the genes activated by the canonical
WNT signaling is the WNT1-inducible signaling pathway
protein 2 (WISP2/ CCN5) (Inadera et al. 2009; Longo et al.
2002) (Pennica et al. 1998).Cnn5/Wisp2 has been shown to be
activated by the canonical WNT and not the non-canonical
WNTsignaling pathways. CCN5/WISP2 has a molecular size
of around 27.5 kDa and the homology between mouse and
human CCN5/WISP2 is high (73%) (Pennica et al. 1998; Wei
et al. 2009). We have also found that human/mouse-CCN5/
WISP2 has similar effects both in human and mouse adipose
cells in vitro.
While the effects of CCNs are diverse in many tissues, this
review will focus on the role of CCN5/WISP2 and its effects
in metabolic diseases, in particular obesity and diabetes.
CCN5/WISP2 and metabolic disease
Metabolic syndrome
CCN5/WISP2 was previously found by microarray analysis
to be one of the genes upregulated in the adipose tissue of First
Degree Relatives (FDR) of patients with type 2 diabetes, a
very high-risk group for the development of diabetes,
Hammarstedt et al. (2013) found the expression of CCN5/
WISP2 to be associated with WNT-regulated genes such as
CYCLIND1, insulin resistance, and markers of hypertrophic
obesity, i.e., increased subcutaneous cell size and waist cir-
cumference in non-diabetic individuals. CCN5/WISP2 was
also positively correlated with markers of ectopic fat accumu-
lation (i.e.,fat in liver or non-subcutaneous / intra-abdominal
adipose tissue) and negatively correlated with whole-body
insulin sensitivity, a marker of risk of developing type 2 dia-
betes. These data provide evidence for increased activation of
canonical WNT in the adipose tissue in the Metabolic
Syndrome.CCN5/WISP2 is highly expressed inmesenchymal
stem cells and undifferentiated preadipocytes and CCN5/
WISP2 protein is not found in isolated mature adipocytes.
During differentiation of both human preadipocytes and mu-
rine 3T3-L1 preadipocytes,CCN5/WISP2 is rapidly downreg-
ulated. However, it remains elevated in the adipose tissue in
hypertrophic obesity/Metabolic Syndrome as a consequence
of the impaired adipogenesis in this condition.
Positive energy balance leads to accumulation of lipids in
the subcutaneous adipose tissue but this tissue has a limited
expandability and, when exceeded, lipids accumulate ectopi-
cally in visceral depots, liver, around the heart, and other or-
gans (Despres et al. 2008; Snel et al. 2012; Virtue and Vidal-
Puig 2010). Experimental studies have shown that this can be
prevented by a hyperplastic adipogenic response as seen, for
instance, in mice overexpressing adiponectin in the adipose
tissue. This leads to an extreme obesity, but of a metabolically
Bhealthy^ phenotype with many small and insulin- sensitive
cells (Kim et al. 2007). Not only obesity, but also lack of
adipose tissue as in genetic lipoatrophy, leads to insulin resis-
tance and ectopic fat accumulation, which can be reversed by
adipose tissue transplantation to allow the lipids to be stored
appropriately (Gavrilova et al. 2000).
CCN5/WISP2 transcriptional activation is higher in subcu-
taneous adipose tissue compared to visceral tissue and also
higher in the adipose tissue in equally obese individuals ful-
filling the criteria for the Metabolic Syndrome. This is likely a
consequence of the impaired adipogenesis in this condition
rather than inappropriate regulation of CCN5/WISP2 activa-
tion. This is supported by our findings in a genetic mouse
model overexpressing Ccn5/Wisp2 in the adipose tissue with
an aP2/FABP4 promoter (aP2-Wisp2) (Grunberg et al. 2017).
These mice demonstrated the positive effect of CCN5/WISP2
on mesenchymal precursor cell growth and subsequent differ-
entiation. The mice had increased glucose tolerance, insulin
sensitivity, and hyperplastic brown and white adipose tissues
withmore numerous but smaller adipocytes. These results will
be further discussed later in this review.
CCN5/WISP2 and adipogenesis
The ability to recruit and commit MSCs to the adipogenic
lineage is crucial for a healthy expansion of the adipose tissue
during weight expansion rather than merely enlarging the
available cells. Furthermore, there is a 10% annual turnover
of the adipose cells in man (Arner et al. 2010). Thus, there is a
continuous recruitment of progenitor cells which undergo sub-
sequent differentiation to new adipose cells. CCN5/WISP2
has profound effects on both adipogenic commitment and
differentiation of adipocytes (Hammarstedt et al. 2013). Like
other CCN proteins (Perbal 2013), CCN5/WISP2 is both pres-
ent in the cytosol and secreted, and prevents adipogenic com-
mitment and PPARγ-induced differentiation through two dif-
ferent mechanisms. Cytosolic CCN5/WISP2 forms a complex
with the PPARγ transcriptional co-activator ZNF423 (Gupta
et al. 2010). This prevents ZNF423 from entering the nucleus
and activating transcriptional programs that allow the cells to
enter commitment to the adipocyte l ineage. The
CCN5/WISP2-ZNF423-complex is dissociated by BMP4
through the SMAD binding domain on ZNF423 which then
allows its nuclear entry. BMP4 is also an important inhibitor
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of ZNF423 in mesenchymal progenitor cells (Grunberg et al.
2014). Together, these are important mechanisms for
adipogenic commitment of mesenchymal progenitor cells as
also shown by the induction of adipogenic markers when
CCN5/WISP2 is silenced by BMP4. The secretion of BMP4
inhibitors such as Gremlin 1 in human cells (Gustafson et al.
2015) or Noggin in murine cells (Gustafson and Smith 2012)
prevents the ability of BMP4 to dissociate the CCN5/WISP2-
ZNF423-complex and as a consequence, also adipogenic dif-
ferentiation. The adipose tissue secretes endogenous BMP4,
and this is enhanced in obesity, in order to promote the recruit-
ment of new progenitor cells rather than merely expanding
available cells and developing a dysfunctional hypertrophic
obesity. The importance of the endogenous and secreted
BMP inhibitors in preventing BMP4-induced precursor cell
adipogenic commitment and differentiation and developing
an adipose tissue BMP4 resistance has been shown in both
human (Gustafson et al. 2015) and murine cells (Hoffmann
et al. 2017).
Secreted CCN5/WISP2 promotes proliferation of mesen-
chymal precursor cells but also inhibits their adipogenic com-
mitment and differentiation (Grunberg et al. 2014;
Hammarstedt et al. 2013). Like the canonical WNT3a ligand
(Gustafson and Smith 2010), it activates the canonical WNT
pathway and prevents PPARγ-activation. Thus, CCN5/
WISP2 is not only induced by canonical WNT activation but
it also, in part, signals through the same pathway. Secreted
CCN5/WISP2 initiates transcriptional activation of Tcf/Lef
and directs β-catenin to the nucleus, whereas silencing of
Ccn5/Wisp2 leads to a decrease in β-catenin as well as its
nuclear-targeted phosphorylation. The specific receptor for
CCN5/WISP2 is currently unknown but is it unlikely to be a
member of the Frizzled family of receptors as discussed
below.
CCN5/WISP2 receptor and signaling
The specific CCN5/WISP2 receptor is currently unknown but
LRP5/6 is a potential candidate. LRP5/6 is a co-receptor for
canonical WNT and TGFβ as well as several other ligands
including CTGF and PDGFα through physical interaction
with the cognate receptors (Ren et al. 2013). CCN5/WISP2
does not need acylation for its secretion (Grunberg et al. 2014)
while other conventional canonical WNT ligands have to be
acylated in order to be secreted and bind to the FZD receptors
(Clevers and Nusse 2012; Willert and Nusse 2012). Thus,
CCN5/WISP2 may bind to the LRP5/6 receptor directly
and/or activate it through other signaling pathways.
Additional supporting evidence that CCN5/WISP2 signals
through the LRP5/6 receptor is the finding that the canonical
WNT inhibitor DKK1 antagonizes the inhibitory effect of
CCN5/WISP2 on Pparg and Fabp4 transcriptional activation
(Grunberg et al. 2014). DKK1 is a both a marker and mediator
of well-functioning adipogenesis (Christodoulides et al. 2006)
and can partly rescue the impaired adipogenesis in hypertro-
phic obesity further supporting the importance of secreted
CCN5/WISP2 in regulating adipogenesis (Gustafson and
Smith 2012). How DKK1 and other canonical WNT antago-
nists are regulated is currently unclear but PPARγ activation
can increase the secretion of DKK1 in adipose cells
(Gustafson et al. 2010). Once PPARγ is activated it sup-
presses WNT-activation by increasing the degradation of β-
catenin and thus maintaining the differentiated state
(Gustafson et al. 2010; Liu et al. 2006).
It has also been shown that CCN5/WISP2 interacts with the
cell surface receptor integrin αvβ3 in vascular smooth muscle
cells (VSMC) and podosomes, but the downstream signaling
effects are unknown. CCN5/WISP2 does, however, prevent
the matrix degradation required for cell migration in
podosomes (Myers et al. 2014). This is further supported by
data from the Castellot laboratory showing that ectopic ex-
pression of CCN5/WISP2 in a mouse model for vascular re-
stenosis strongly suppresses VSMC migration and prolifera-
tion. It was suggested that CCN5/WISP2 protects against re-
stenosis by blocking the ability of medial VSMC podosomes
to degrade matrix, thus preventing migration into the intima
(Myers et al. 2014).
Integrin αvβ3 is a promiscuous receptor that binds a wide
range of proteins (Myers et al. 2014) and it is possible that
CCN5/WISP2 also interacts with integrin αvβ3 to mediate
further downstream signaling including MAPK activation.
We found both p38 MAPK and ERK MAPKinases to be
activated by CCN5/WISP2 in mature adipocytes (Grunberg
et al. 2014). However, further studies are needed to clarify the
potential cross-talk between CCN5/WISP2 and integrin
αvβ3.
Regulation of CCN5/WISP2
Ccn5/Wisp2 transcript begins to be expressed at the early me-
dulla stage (12–16 cells) in embryogenesis and it persists in all
three germ layers (endoderm, mesoderm, and ectoderm)
throughout the embryonic development in mice. The CCN5/
WISP2 protein is present in most cells of early embryos and is
not restricted to a particular germ layer in mice and humans.
Tissue specificity appears as the embryo develops. In adult
rodents, CCN5/WISP2 is widely distributed in many cell
types, both in the cytosol and the nuclei, but CCN5/WISP2
has not been found in the nucleus of mouse and rat pancreas,
liver, or spleen (Gray et al. 2007; Jones et al. 2007; Myers
et al. 2012; Wiesman et al. 2010).
Canonical WNT3a and GSK3β inhibition increases Ccn5/
Wisp2 expression (2–3 times) in mesenchymal stem/precursor
cells (Hammarstedt et al. 2013), as well as insulin like growth
factor 1 (IGF-1) levels in murine pancreatic beta cells
(Chowdhury et al. 2014), but the detailed regulation of
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CCN5/WISP2 is largely unknown. Ccn5/Wisp2 expression is
associated with IGF-1 induced islet cell survival and prolifer-
ation. Interestingly, miRNA 450a-5p inhibits both the CCN5/
WISP2 mRNA and protein levels in a dose-dependent manner
in exosome-like vesicles derived from rat adipose tissue
(Zhang et al. 2017).
The CCN5/WISP2 promoter contains TCF, hypoxia induc-
ible factor (HIF), and nuclear factor kappa-light-chain-
enhancer of activated B cells (NFκβ) sequences as well as
binding domains for PPARγ and its transcriptional co-
activator ZFP423. CCN5/WISP2 is regulated by hypoxia
through the HIFα isoforms in low-invasive luminal-like
breast cancer cell lines, preferentially by HIF2α. CCN5/
WISP2 is also negatively correlated with tumor macrophage
invasion in breast cancer samples which could provide an
additional marker for a better tumor prognosis (Fuady et al.
2014). CCN5/WISP2 has also been reported to be directly
regulated by estrogen in the human breast cancer cell line
MCF-7 and non-transformed human mammary epithelial
cells, and is more highly expressed in a less-aggressive breast
cancer cell line (MCF-7) compared with a highly aggressive
(MDA-MB-231) (Banerjee and Banerjee 2012; Inadera 2003;
Inadera et al. 2000; Zoubine et al. 2001).
Expression data from 79 human tissues showed thatCCN5/
WISP2 is by far most highly expressed in the adipose tissue
(upregulated 950 times) (Online_database_BIOGPS 2015).
Similar to the findings by Hammarstedt et al. (Hammarstedt
et al. 2013), the secretome of human adipose tissue was ana-
lyzed and showed that CCN5/WISP2 is a highly secreted
adipokine that is downregulated in the visceral adipose
tissue, compared with the subcutaneous adipose tissue,
and correlated to obesity (Dahlman et al. 2012).
Furthermore, CCN5/WISP2 expression has been impli-
cated to be a marker of number and/or activity of adi-
pose precursor cell populations and extracellular matrix
remodeling in cattle and a good predictor of intramus-
cular fat, i.e., marbling of the meat that impacts flavor
and juiciness (Hudson et al. 2014).
The in vivo effects of CCN5/WISP2 in the adipose tissue
have been studied using the aP2-Wisp2 mice (Grunberg et al.
2017). The aP2-Wisp2 mice showed a completely different
phenotype compared with other in vivo models studying the
metabolic consequences of canonical WNT. WNT10b over-
expression under the aP2-promoter displayed an obesity-
protected phenotype with reduced brown and white adipose
tissue, reduced weight and the mice were not insulin resistant
(Wright et al. 2007). Overexpressing activated β-catenin in
PPARγ-expressing adipose precursor cells showed a similar
lipodystrophic phenotype while using the later aP2-promoter
in differentiated cells did not produce a clear phenotype.
Moreover, mice overexpressing β-catenin in the precursor
cells were found to release unidentified factor(s) that increased
glucose uptake in muscles ex vivo (Zeve et al. 2012).
Transgenic aP2-Wisp2 mice (Grunberg et al. 2017) (Tg) on
high fat diet (HFD) had similar body weight and were more
insulin-sensitive during both non- and steady state conditions
and this was also validated ex vivo. There were several
markers of increased mesenchymal tissue growth such as in-
creased and hyperplastic BAT, lean body mass, and weight of
skeletal muscles/heart. Serum from Tg mice promoted prolif-
eration of mesenchymal precursor cells and this effect was
inhibited by CCN5/WISP2 monoclonal antibodies, verifying
the direct proliferative effect of elevated levels of CCN5/
WISP2 in the circulation.
During HFD in mice, both subcutaneous (sWAT) and epi-
didymal adipose tissue (eWAT) starts to expand through hy-
pertrophy during an early stage. After prolonged caloric ex-
cess (1 month), the eWAT initiates adipogenesis, i.e., hyper-
plasia, which is not seen in the sWAT depots (Wang et al.
2013). However, sWAT in the Tg mice was hyperplastic and
characterized by smaller cells, both by mean cell size and total
distribution (Fig. 1). This Bhealthy^ adipose tissue profile can
probably account for the finding that the Tg mice were more
insulin sensitive and had higher circulating adiponectin levels
as well as transcriptional activation in the adipose tissue.
However, there were no signs of increased beige markers in
the white adipose tissues (Tbx1, Tmem26, or Cd137) that
could dissipate energy or improve insulin sensitivity (Harms
and Seale 2013; Park et al. 2014; Wu et al. 2012). The in-
creased hypercellular BATmass (Fig. 2) did not showmarkers
of increased activity (unpublished data) with either cold-
exposure or a β3-agonist. Thus, the improved insulin sensi-
tivity is most likely associated with positive metabolic effects
of the increased lean body mass combined with a Bhealthy^
hyperplastic adipose tissue with increased levels adiponectin
and adipose tissue glucose metabolism.
The increased levels of the glucose transporting protein
Glut4 in both adipose tissue and skeletal muscle can be mech-
anistically related to the increased insulin-stimulated glucose
uptake. Increased GLUT4 in the adipose tissue is associated
with increased whole-body insulin sensitivity (Herman et al.
2012). Mice overexpressing GLUT4 under the aP2-promoter
have recently been shown to also have increased de novo
lipogenesis (DNL) regulated by carbohydrate-responsive-
element-binding protein (ChREBPβ) (Herman et al. 2012;
Ussar and Tschop 2014; Yore et al. 2014). ChREBP is acti-
vated by glucose, independent of insulin, and is one of two
major transcription factors for DNL. The other is SREBP-1,
which is activated by insulin (Lodhi et al. 2011; Xu et al.
2013). Activation of DNL by ChREBPβ in GLUT4 mice
leads to increased induction and secretion of lipid species that
are metabolically beneficial, called fatty acid esters of hydrox-
yl fatty acids (FAHFAs), by the adipose tissue (Yore et al.
2014). Chrebp was increased in both adipose depots as well
as other members important for the DNL (Ussar and Tschop
2014; Yore et al. 2014).
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Consequently, we measured several of the novel FAHFAs
in serum and found that obesity induced by HFD was associ-
ated with lower 13/12- and 5-PAHSA while the levels in the
Tg HFD mice were at least as high as in the non-obese mice.
This finding can be a likely mechanism for the increased in-
sulin sensitivity in the HFD Tg mice since FAHFAs also in-
crease glucose uptake (Yore et al. 2014). It is unclear how
increased CCN5/WISP2 leads to increased levels of
FAHFAs but the Bhealthy^ and hypercellular adipose tissue
is a likely contributing factor.
To what extent CCN5/WISP2 - FAHFAs can be related to
the unknown circulating factor(s) mediating the increased glu-
cose uptake seen in mice overexpressing β-catenin in the pre-
cursor cells (Zeve et al. 2012) is currently unclear.
Secreted CCN5/WISP2, under the control of the aP2-
promoter in mice (Grunberg et al. 2017), leads to increased
amount of BAT and hyperplastic subcutaneous adipose tissue
as shown in Fig. 1. This is completely opposite to the results
seen in aP2-Wnt10b or the aP2-activated-β-catenin mice
models as discussed (Wright et al. 2007; Zeve et al. 2012).
This clearly indicates that the proliferative effect of
CCN5/WISP2, albeit being a canonical WNT activator in
the cell studies (Grunberg et al. 2014), also allows the hyper-
plastic precursor cells to enter adipogenesis and undergo dif-
ferentiation. In mesenchymal precursor cells, BMP4 can rap-
idly inhibit Ccn5/Wisp2 transcriptional activation but had no
acute effect on the conventional canonical WNT activator
Wnt10b (Grunberg et al. 2017). Bmp4 expression was in-
creased ≈165% in sWATand eWATas well as BAT in Tg mice
which may be secondary to the increased adipogenesis which
increases cellular BMP4 (Gustafson et al. 2015). However,
this finding adds another dimension to the cross-talk between
Fig. 1 Subcutaneous white adipose tissue visualized by nonlinear
microscopy. Subcutaneous adipose tissue from (a) 19 week old control
Black6/N mouse and (b) transgenic aP2-Wisp2 littermate.. Mice were fed
high-fat diet for 12 weeks prior to termination and CARS analysis of
adipose tissue. Mice were terminated and freshly isolated adipose tissue
was stained with Rhodamine 123 for active mitochondria and analysed
while being kept hydrated at 37 °C. A custom built coherent anti-Stokes
Raman scattering (CARS), second harmonic generation (SHG), and two-
photon excited fluorescence (TPEF) microscope was used to visualize
lipids, collagen, and active mitochondria within the adipose tissue, re-
spectively. Lipids were detected via the 2845 cm−1 symmetric CH2
stretching vibration. All signals were passed through matching bandpass
filters and collected on single photon counting detectors. Lipid droplet
analysis from CARS images has been described previously (Brannmark
et al. 2014)
Fig. 2 Brown intrascapular
adipose tissue visualized by
nonlinear microscopy. Brown
intrascapular adipose tissue from
(a) 19 week old control Black6/N
mouse and (b) transgenic aP2-
Wisp2 littermate. Mice were fed
high-fat diet for 12 weeks prior to
termination and CARS analysis of
adipose tissue
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BMP4 and CCN5/WISP2, where BMP4 is a negative regula-
tor of CCN5/WISP2 expression, but not of the canonical
WNT10b, and thereby allows the expanded mesenchymal
precursor cells to enter normal adipogenic commitment and
differentiation. As discussed, BMP4 is secreted by differenti-
ated pre/adipocytes (Gustafson et al. 2015) and acts as a feed-
back regulator, promoting the entry ofmesenchymal precursor
cells into adipogenic commitment and differentiation (Bowers
et al. 2006; Gustafson and Smith 2012).
Taken together, CCN5/WISP2 is an endogenous and se-
creted auto/paracrine non-conventional WNT ligand,
targeting mesenchymal precursor cells and promoting their
growth and expansion.
CCN5/WISP2 plays several roles in the regulation of adi-
pogenesis by both promoting precursor cell proliferation and
tissue growth, by regulating precursor cell commitment in
response to BMP4 as well as the subsequent differentiation
and PPARγ induction. In addition, as a secreted molecule,
CCN5/WISP2 can exert autocrine, paracrine, and also endo-
crine regulation and be an important adipokine mediating
cross-talk between the adipose tissue and other cells. In order
to induce adipogenesis, CCN5/WISP2 has to be inhibited by
external signals and the key adipose progenitor cell commit-
ment factor BMP4 also inhibits CCN5/WISP2(Grunberg
et al. 2017).
Thus, CCN5/WISP2 is a novel regulator of mesenchymal
tissue growth and development and can, thereby, also be an
important target for preventing obesity- related metabolic
complications.
CCN5/WISP2 is anti-fibrotic in contrast to CTGF
The expanded adipose tissue in hypertrophic obesity is char-
acterized by increased tissue fibrosis. However, fibrosis was
not increased in the aP2-Wisp2 Tg mice (Grunberg et al.
2017), possibly because of the hyperplastic adipose tissue
with smaller adipocytes in the subcutaneous depots (Fig. 1).
A heart muscle-specific CCN5/WISP2 overexpressing mouse
model, using α-myosine heavy chain as promoter, further
supported the anti-fibrotic effect of CCN5/WISP2. CCN5/
WISP2 was shown to protect from cardiac hypertrophy and
fibrosis in response to pressure overload when compared to a
CTGF-overexpressing model (Yoon et al. 2010). If this is
because CCN5/WISP2 does not directly induce fibrosis or if
it does not enhance the TGFβ-pathway like CTGF is un-
known (Parada et al. 2013; Yoon et al. 2010). The activation
of both the canonical WNT and TGFβ signaling pathways
have been shown to be required for induction of fibrosis
(Akhmetshina et al. 2012).
There is mounting evidence that CCN5/WISP2 is anti-
fibrotic and counteracts the effects of several fibrotic markers
such as CTGF and α-SMA (Xu et al. 2015a; Xu et al. 2015b).
In rat scar tissue, where epidural fibrosis was examined,
CTGF was upregulated while CCN5/WISP2 was downregu-
lated on both mRNA and protein level. Overexpression of
Ccn5/Wisp2 in rat fibroblasts from tail skin diminished ex-
pression of the myofibroblast marker α-SMA and total colla-
gen concentrations as well as collagen type 1α1 (COL1A1)
were decreased. This supports that Ccn5/Wisp2 inhibits fibro-
blast to myofibroblast transition (Xu et al. 2015b), which also
was shown in human lung fibroblasts (Zhang et al. 2014) and
murine cardiac fibroblasts (Jeong et al. 2016).
Furthermore, overexpression of Ccn5/Wisp2 in human pri-
mary skin fibroblasts reduces TGFβ1-induced activation of
CTGF as well as their proliferation and differentiation (Xu
et al. 2015a).
Both CTGF and CCN5/WISP2 belong to the CCN family
of proteins and have a very similar structure. However, unlike
the rest of the family members CCN5/WISP2 lacks the cyste-
ine knot (CT) domain. By fusing CCN5/WISP2 with the CT-
domain, CCN5/WISP2 gained CTGF-like properties in the
same fibroblasts. These results further demonstrate the oppos-
ing effects of CCN5/WISP2 and CTGF (Xu et al. 2015a).
The anti-fibrotic effects of CCN5/WISP2 were further val-
idated in patients with heart failure. TGFβ mediates cardiac
fibrosis and CCN5/WISP2 expression is strongly downregu-
lated in patients with heart failure whereas CTGF is increased
(Jeong et al. 2016). This was also observed in mice with heart
failure from transverse aortic constriction. However, heart
specific overexpression of Ccn5/Wisp2, through AAV9-virus-
es, preserved echocardiographic parameters, with inhibition of
the TGFβ-pathway and several fibrotic genes (Jeong et al.
2016). Notably, overexpression of Ccn5/Wisp2 not only
prevented, but actually reversed, cardiac fibrosis. Taken to-
gether, these data add more evidence to the inhibitory effect
of CCN5/WISP2 on TGFβ signaling (Jeong et al. 2016).
The Smad proteins, PI3K/Akt and JNK pathways have
been suggested to be involved in TGFβ1 induced fibrosis
(Conte et al. 2011). Overexpression of Ccn5/Wisp2 reduced
both Smad2 and JNK phosphorylation induced by TGFβ1
(Zhang et al. 2014). In addition, phosphorylation of Akt1
was reduced and the effects of Ccn5/Wisp2 overexpression
were similar to those of a PI3K inhibitor (LY294002). This
indicates that the Smad-independent PI3K/Akt pathway is af-
fected in the inhibitory effects of CCN5/WISP2 on fibrosis
and CCN5/WISP2 might exert signaling through Smad6
phosphorylation. TGFβ1 is a key mediator in fibrosis progres-
sion by activation of its downstream Smad signaling pathway.
However, Smad6 can prevent the phosphorylation of other
Smad members and therefore act as a negative regulator of
the TGFβ mediated pathway (Imamura et al. 1997) and pre-
vious studies have shown that silencing CCN5/WISP2 expres-
sion in the breast cancer cell line MCF-7 decreases Smad6
expression levels (Sabbah et al. 2011). Blocking Smad6 phos-
phorylation ameliorated the inhibitory effect of CCN5/WISP2
on CTGF. When the Smad6 pathway was blocked using
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siRNA, cell proliferation was once again increased in Ccn5/
Wisp2-overexpressing cells following TGFβ1 stimulation
(Xu et al. 2015b). CCN5/WISP2 also normalized the in-
creased Akt phosphorylation induced by TGFβ in cardiac
fibroblasts, consistent with the findings seen in fibroblasts of
the lung (Jeong et al. 2016; Zhang et al. 2014).
Can CCN5/WISP2 be useful in regenerative
medicine?
Because of their multilineage potential, ease of isolation com-
pared with embryonic stem cells, fewer ethical issues, and
safer profile in terms of oncogenicity (Ren et al. 2012),
MSCs have become of interest in the field of regenerative
medicine. An exciting new area of translational research is
currently investigating the therapeutic potential of MSCs in
tissue repair. MSCs can easily be amplified in vitro while
retaining their multipotent potential and are proven safe for
autologous transplantation. Furthermore,MSCs are capable of
homing to lesion areas and migrate into the injured site guided
by chemokines released, which potentially simplify the route
of administration (Salem and Thiemermann 2010). Since
CCN5/WISP2 enhances growth of mesenchymal precursor
cells and induces hyperplastic expansion of mesenchymal tis-
sues in transgenic animals (Grunberg et al. 2017), it may also
become a target in regenerative medicine and tissue repair.
It is established that the beneficial outcomes of MSCs
transplantation occur through paracrine release of biological
factors that affect vascular development, are anti-fibrotic and
anti-inflammatory facilitating the endogenous repair process
rather than direct engraftment into the recipient tissue.
In fact, studies investigating the effect of MSC transplan-
tation, or other stem cell-like cells, in patients with heart fail-
ure have shown that the retention and engraftment of
transplanted MSCs in the myocardium is disproportional in
size and duration to the functional benefits reported. These
indirect effects have been attributed to both cell-cell contact
and the production and release of positive endocrine factors
(Chen et al. 2017; Gnecchi et al. 2008; Leiker et al. 2008).
Although inflammation is a natural and necessary response
by the body to many challenges, excessive or prolonged in-
flammatory stress is harmful for many tissues, not least in the
case of adipose tissue contribution to the Metabolic Syndrome
and T2D. Interestingly, studies have shown that MCSs can
modulate key inflammatory cells in the innate and adaptive
immune system making them less inflammatory and instead
induce protective cytokines (Gao et al. 2016; Pers et al. 2015;
Wang et al. 2012). Consequently, many of the current MCS-
based transplantation studies have been performed with the
intention to treat immune disorders and with demonstrated
clinical potential (Ren et al. 2012). Substantial progress has
also been made using MSC in some neurodegenerative
diseases where immunomodulation has played a central role
in ameliorating disease symptoms (Volkman and Offen 2017).
The possibilities of MSCs have also generated clinical in-
terest in the field of T2D. The studies involve diabetes-related
vascular problems and wound healing, but also autologous
transplantation of MSCs to improve insulin secretion in pa-
tients with newly diagnosed type 1 diabetes or established
T2D. The results have been cautiously positive (Moreira
et al. 2017).
Clearly, MSC transplantation and identification of factors
that promote endogenous MSC activation and tissue regener-
ation represent clinically relevant solutions for the treatment
of many disease conditions. However, although considerable
advances have been made in this area, many issues still need
to be clarified before it can be routinely used as a therapeutic
option.
In sum, CCN5/WISP2 is a growth factor of MSCs and may
become useful for restoring tissue growth after damage and/or
as an anti-inflammatory and anti-fibrotic factor in human
disease.
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